SAB Biotherapeutics SABS
NASDAQ SABS
$3.06 -0.11 (-3.47%)
At close: Oct 1, 2026 · 4:00 PM EDT

SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021)

Updated

SAB Biotherapeutics' Long-Term Debt Issuances came in at $515,986 for FY2024, down 32.6% from $765,194 in FY2023.

Analysis

SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

Going back to FY2021, SAB Biotherapeutics' Long-Term Debt Issuances data covers 4 years.

  • Long-Term Debt Issuances has declined in each of the last three years, with a three-year compound annual growth rate of -43.4% (FY2021 to FY2024).
  • Per Business Quant, earlier years put Long-Term Debt Issuances at $765,194 in FY2023 (-38.1%), $1.24 million in FY2022 (-56.5%) and $2.84 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 1.98 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 SAB Biotherapeutics 264.67 Mn 264.67 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 150,000.00
Dec 31, 2020 150,000.00
API Access

SAB Biotherapeutics Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=SABS&period=max&api_key=YOUR_API_KEY